Your session is about to expire
← Back to Search
Neoadjuvant Chemotherapy for Pancreatic Cancer
Study Summary
This trial explores the impact of using two FDA-approved chemo drugs to treat pancreatic cancer in a new sequence.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had chemotherapy with gemcitabine, nab-paclitaxel, or FOLFIRINOX for pancreatic cancer.I haven't had cancer in the last 3 years, except for certain skin, cervical, or low-risk prostate cancers.I do not have any severe illnesses or social situations that would affect my study participation.I haven't had any major surgery in the last 4 weeks.I am fully active or can carry out light work.My blood and organ functions meet the required levels for the trial.I can understand and am willing to sign the consent form.I am 18 years old or older.I have a lung condition but don't need oxygen support.My cancer is primarily pancreatic adenocarcinoma.My pancreatic cancer is advanced but hasn't spread far and fits certain guidelines.I do not have an ongoing serious infection or have completed treatment for it.
- Group 1: Neoadjuvant Chemotherapy (Gemcitabine and nab-Paclitaxel and mFOLFIRNIOX)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies for participants in this medical study?
"Clinicaltrials.gov states that this research trial, initially posted on the 1st of June 2023 and revised on April 19th 2023, is not presently recruiting participants. However, there are 798 other experiments searching for volunteers currently open to enrollment."
Has the FDA validated Neoadjuvant Chemotherapy (Gemcitabine and nab-Paclitaxel and mFOLFIRNIOX)?
"A score of 2 was given to Neoadjuvant Chemotherapy (Gemcitabine and nab-Paclitaxel and mFOLFIRNIOX) due to the fact that there is evidence suggesting it may be safe, yet no data proving its efficacy."
What is the ultimate goal of this research endeavor?
"Through the course of this nine-month trial, researchers will be assessing the R0 Resection Rate - Locally Advanced prostate cancer Participants. Secondary observations are set to include: a count of participants that complete four cycles of sequential chemotherapy; progression-free survival (PFS) which is evaluated through RECIST v1.1 guidelines as well as overall survival (OS). Stratified Kaplan-Meier curves are employed to assess PFS and OS with estimated 6 month and median times being provided alongside 95% confidence intervals."
Share this study with friends
Copy Link
Messenger